Clinical trial
A Phase 2A, Randomized, Double-Blind, Dose Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets Compared to Fluconazole in the Treatment of Patients With Moderate to Severe Acute Vulvovaginal Candidiasis
NCT01891331 is registered in ClinicalTrials.gov with Viamet as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2A, Randomized, Double-Blind, Dose Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets Compared to Fluconazole in the Treatment of Patients With Moderate to Severe Acute Vulvovaginal Candidiasis
- Lead sponsor
- Viamet
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 31, 2013
- Completion date
- December 31, 2014
- Enrollment
- 55 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.